Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency
Public ClinicalTrials.gov record NCT01502124. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Norditropin® and Norditropin® Cartridges: An Open-Label, Randomized, Comparative Safety and Efficacy Trial in Children With Growth Hormone Deficiency
Study identification
- NCT ID
- NCT01502124
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 78 participants
Conditions and interventions
Interventions
- somatropin Drug
Drug
Eligibility (public fields only)
- Age range
- 3 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 7, 2001
- Primary completion
- Mar 4, 2003
- Completion
- Mar 4, 2003
- Last update posted
- Feb 27, 2017
2001 – 2003
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Los Angeles | California | 90027 | — |
| Novo Nordisk Investigational Site | Los Angeles | California | 90048-1869 | — |
| Novo Nordisk Investigational Site | Wilmington | Delaware | 19899 | — |
| Novo Nordisk Investigational Site | Washington D.C. | District of Columbia | 20010 | — |
| Novo Nordisk Investigational Site | Gainesville | Florida | 32608 | — |
| Novo Nordisk Investigational Site | Miami | Florida | 33155 | — |
| Novo Nordisk Investigational Site | Orlando | Florida | 32806-1101 | — |
| Novo Nordisk Investigational Site | Tampa | Florida | 33607 | — |
| Novo Nordisk Investigational Site | Atlanta | Georgia | 30342 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60612 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60614 | — |
| Novo Nordisk Investigational Site | Wichita | Kansas | 67226 | — |
| Novo Nordisk Investigational Site | Lexington | Kentucky | 40536-0284 | — |
| Novo Nordisk Investigational Site | Louisville | Kentucky | 40202 | — |
| Novo Nordisk Investigational Site | Worcester | Massachusetts | 01655 | — |
| Novo Nordisk Investigational Site | Manhasset | New York | 11030 | — |
| Novo Nordisk Investigational Site | Akron | Ohio | 44308-1062 | — |
| Novo Nordisk Investigational Site | Hershey | Pennsylvania | 17033 | — |
| Novo Nordisk Investigational Site | Pittsburgh | Pennsylvania | 15212 | — |
| Novo Nordisk Investigational Site | Pittsburgh | Pennsylvania | 15224 | — |
| Novo Nordisk Investigational Site | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01502124, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2017 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01502124 live on ClinicalTrials.gov.